Biotech Values

[DewDiligence]

ALNY CC post-mortem:

There were two questions that needed to be asked and answered:

1. Does ALNY’s RNAi-delivery technology really make siRNAs go to the organ(s) where the siRNAs are therapeutically useful… or are the siRNAs going to the liver merely because the body is excreting them as it would excrete any waste material?

2. If the RNAi-delivery technology featured in the Nature article is so great, why does ALNY need another one (the one they licensed today from Inex)?

Both questions were asked but, alas, the questions were framed as typical Wall Street softballs that allowed ALNY’s CEO to issue boilerplate non-answer answers.

My inference (FWIW) is that ALNY hasn’t really solved the RNAi-delivery problem—and may not even be close to solving it. The siRNAs described in the Nature article are merely going through the liver as any waste material would.